These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 15083196)
1. Improved biological activity of a mutant endostatin containing a single amino-acid substitution. Yokoyama Y; Ramakrishnan S Br J Cancer; 2004 Apr; 90(8):1627-35. PubMed ID: 15083196 [TBL] [Abstract][Full Text] [Related]
2. Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth. Yokoyama Y; Ramakrishnan S Int J Cancer; 2004 Oct; 111(6):839-48. PubMed ID: 15300795 [TBL] [Abstract][Full Text] [Related]
3. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth. Yokoyama Y; Ramakrishnan S Cancer; 2005 Jul; 104(2):321-31. PubMed ID: 15952188 [TBL] [Abstract][Full Text] [Related]
4. Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Subramanian IV; Ghebre R; Ramakrishnan S Gene Ther; 2005 Jan; 12(1):30-8. PubMed ID: 15550927 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins. Jing Y; Lu H; Wu K; Subramanian IV; Ramakrishnan S Int J Cancer; 2011 Aug; 129(3):751-61. PubMed ID: 21225621 [TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy. Shin SU; Cho HM; Merchan J; Zhang J; Kovacs K; Jing Y; Ramakrishnan S; Rosenblatt JD Mol Cancer Ther; 2011 Apr; 10(4):603-14. PubMed ID: 21393427 [TBL] [Abstract][Full Text] [Related]
7. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. Morbidelli L; Donnini S; Chillemi F; Giachetti A; Ziche M Clin Cancer Res; 2003 Nov; 9(14):5358-69. PubMed ID: 14614021 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases. Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD Cells; 2021 Oct; 10(11):. PubMed ID: 34831127 [TBL] [Abstract][Full Text] [Related]
9. Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Subramanian IV; Bui Nguyen TM; Truskinovsky AM; Tolar J; Blazar BR; Ramakrishnan S Cancer Res; 2006 Apr; 66(8):4319-28. PubMed ID: 16618757 [TBL] [Abstract][Full Text] [Related]
10. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Olsson AK; Johansson I; Akerud H; Einarsson B; Christofferson R; Sasaki T; Timpl R; Claesson-Welsh L Cancer Res; 2004 Dec; 64(24):9012-7. PubMed ID: 15604266 [TBL] [Abstract][Full Text] [Related]
11. The anti-angiogenic activity of human endostatin inhibits bladder cancer growth and its mechanism. Du Z; Hou S J Urol; 2003 Nov; 170(5):2000-3. PubMed ID: 14532841 [TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization. Bai Y; Zhao M; Zhang C; Li S; Qi Y; Wang B; Huang L; Li X PLoS One; 2014; 9(11):e112448. PubMed ID: 25380141 [TBL] [Abstract][Full Text] [Related]
13. AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer. Subramanian IV; Devineni S; Ghebre R; Ghosh G; Joshi HP; Jing Y; Truskinovsky AM; Ramakrishnan S Gene Ther; 2011 Feb; 18(2):145-54. PubMed ID: 20844568 [TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Chen CT; Lin J; Li Q; Phipps SS; Jakubczak JL; Stewart DA; Skripchenko Y; Forry-Schaudies S; Wood J; Schnell C; Hallenbeck PL Hum Gene Ther; 2000 Sep; 11(14):1983-96. PubMed ID: 11020798 [TBL] [Abstract][Full Text] [Related]
15. Endostatin inhibits the tumorigenesis of hemangioendothelioma via downregulation of CXCL1. Guo L; Song N; He T; Qi F; Zheng S; Xu XG; Fu Y; Chen HD; Luo Y Mol Carcinog; 2015 Nov; 54(11):1340-53. PubMed ID: 25175281 [TBL] [Abstract][Full Text] [Related]
16. The antiangiogenic and antitumor activities of the N-terminal fragment of endostatin augmented by Ile/Arg substitution: The overall structure implicated the biological activity. Chamani R; Asghari SM; Alizadeh AM; Mansouri K; Doroudi T; Kolivand PH; Ghafouri H; Ehtesham S; Rabouti H; Mehrnejad F Biochim Biophys Acta; 2016 Dec; 1864(12):1765-1774. PubMed ID: 27693049 [TBL] [Abstract][Full Text] [Related]
17. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Dkhissi F; Lu H; Soria C; Opolon P; Griscelli F; Liu H; Khattar P; Mishal Z; Perricaudet M; Li H Hum Gene Ther; 2003 Jul; 14(10):997-1008. PubMed ID: 12869217 [TBL] [Abstract][Full Text] [Related]
18. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer. Isayeva T; Ren C; Ponnazhagan S Clin Cancer Res; 2005 Feb; 11(3):1342-7. PubMed ID: 15709207 [TBL] [Abstract][Full Text] [Related]
19. Antiangiogenesis effects of endostatin in retinal neovascularization. Bai YJ; Huang LZ; Zhou AY; Zhao M; Yu WZ; Li XX J Ocul Pharmacol Ther; 2013 Sep; 29(7):619-26. PubMed ID: 23545016 [TBL] [Abstract][Full Text] [Related]
20. N-/C-terminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent. Cho H; Kim WJ; Lee YM; Kim YM; Kwon YG; Park YS; Choi EY; Kim KW Oncol Rep; 2004 Jan; 11(1):191-5. PubMed ID: 14654925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]